BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 09, 2006
 |  BioCentury  |  Finance

New products to watch

New products to watch

Company Product Indication 2005 approval
Alkermes (ALKS)/Cephalon (CEPH) Vivitrol (formerly Vivitrex) Alcohol dependence U.S. approvable letter
Amgen (AMGN) Kepivance Oral mucositis EU (already approved in U.S.)
Amylin (AMLN) Symlin Type I and II diabetes in conjunction with insulin U.S.
Amylin (AMLN) Byetta Type II diabetes U.S.
Bayer (FSE:BAYG; BAY)/ Nexavar Advanced renal cell carcinoma (RCC) U.S.
Onyx (ONXX)
BioMarin (SWX:BMRN; BMRN)...

Read the full 489 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >